Although the monodrug therapy that inhibited CTLA-4 pathway failed in improving OS in NSCLC patients [38], PD-1/PD-L1 (PD-1 ligand 1) checkpoint inhibitors have shown impressive results that have changed the landscape of NSCLC therapy [44–46]. Here, CTLA4 is linked to non-small cell lung carcinoma.